

## LEGEND-T2DM Evidence Dissemination Summary


Target: **linagliptin**, Comparator: **glipizide** Outcome: **Edema**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	-	-	-	-
Merative CCAE	5,865	4,026	187	46.45
Merative MDCCD	1,783	1,101	110	99.91
Merative MDCR	1,288	1,182	123	104.03
Optum Clinformatics	9,094	6,807	514	75.51
Optum EHR	7,219	1,405	114	81.12
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator 
 ■ Target 
 ■ Before 
 ■ After 
 ■ MDRR 
 ● Negative control 
 ◆ Calibrated estimate



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR 
 ● Negative control 
 ◆ Estimate 
 ◆ Calibrated estimate

